64 articles, transcripts, and reports
Merck & Co Inc (NYSE:MRK) Q4 2022 Earnings Call dated Feb. 02, 2023. Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Robert M. Davis — Chairman and Chief…
Merck (NYSE: MRK) reported fourth quarter 2022 earnings results today. Sales increased 2% year-over-year to $13.8 billion. GAAP net income fell 17% to $3 billion,…
Merck & Co Inc (NYSE:MRK) Q3 2022 Earnings Call dated Oct. 27, 2022. Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations Robert M. Davis — Chief Executive…
Merck & Co., Inc. (NYSE: MRK) reported a modest increase in adjusted earnings for the third quarter of 2022 when the pharmaceutical company’s net sales…
Merck & Co., Inc. (NYSE: MRK) is recovering from the virus-induced slowdown supported by stable demand across its product line globally, a trend the pharmaceutical…
Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than-expected earnings and revenues for the first quarter of 2022. The positive outcome reflects significant clinical…
Merck & Co., Inc. (NYSE: MRK) Q1 2022 Earnings Conference
Merck & Co. Inc. (NYSE: MRK) Q1 2022 earnings call dated Apr. 28, 2022 Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations Robert M. Davis — President,…
Merck & Co., Inc. (NYSE: MRK) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations Robert M. Davis — Chief…
Merck & Co., Inc. (NYSE: MRK) Q4 2021 Earnings Conference
